Accretive Acquisition
Key Takeaways
- An accretive acquisition increases the acquiring company's earnings per share (EPS) after the deal closes
- Accretion occurs when the target's earnings contribution exceeds the financing cost and dilution from the acquisition
- Accretive deals are generally viewed favorably by investors and analysts
- Being accretive does not automatically mean a deal creates long-term shareholder value
Definition
An accretive acquisition is a merger or acquisition that increases the acquiring company's earnings per share (EPS) on a pro forma basis. This occurs when the target company's earnings contribute more to the combined entity's bottom line than the cost of financing the deal, including any dilution from issuing new shares.
The opposite of an accretive acquisition is a dilutive acquisition, which decreases the acquirer's EPS. Accretion and dilution analysis is a standard component of M&A financial modeling and is closely watched by analysts and investors as a key measure of deal quality.
It is important to note that accretion is a near-term financial metric and does not necessarily indicate whether an acquisition is strategically sound. A deal can be accretive to EPS but still destroy shareholder value if the acquirer overpays, if synergies fail to materialize, or if the acquisition distracts management from more productive uses of capital.
How It Works
To determine whether an acquisition is accretive, analysts build a pro forma financial model combining the two companies' income statements. The key comparison is between the target's net income contribution and the cost of the acquisition. If the deal is financed with cash, the cost is the foregone interest income or the interest expense on new debt. If financed with stock, the cost is the dilution from issuing additional shares.
For example, if an acquirer with 100 million shares and $500 million in net income ($5.00 EPS) acquires a company earning $100 million by issuing 15 million new shares, the combined entity earns $600 million on 115 million shares, or $5.22 EPS. Since $5.22 exceeds the original $5.00, the deal is accretive. If the acquirer had to issue 25 million shares instead, the combined EPS would be $4.80, making the deal dilutive.
Analysts typically model accretion/dilution for the first full year after closing and for subsequent years as synergies are realized. A deal may be initially dilutive but become accretive in year two or three as cost savings are achieved. Investment bankers present this analysis to acquirer boards and shareholders to demonstrate the financial impact of a proposed transaction.
Example
When AbbVie (ABBV) acquired Allergan for $63 billion in 2020, AbbVie projected the deal would be accretive to its EPS in the first full year after closing. Allergan's portfolio, anchored by Botox, added significant earnings that more than offset the financing costs and dilution from the stock-and-cash transaction. AbbVie's management emphasized the deal's accretive nature to reassure investors who were concerned about the size of the acquisition and AbbVie's growing debt load. The deal did prove accretive as projected, helping AbbVie diversify its revenue base as its blockbuster drug Humira faced biosimilar competition.
Why It Matters
Accretion analysis is one of the most widely used metrics for evaluating M&A transactions. Investors and analysts use it as a quick test of whether a deal makes financial sense. Accretive deals are generally received positively by the market because they signal that the acquisition will immediately boost per-share profitability.
However, investors should not rely solely on accretion as a measure of deal quality. A deal can be accretive simply because the acquirer's stock trades at a high P/E multiple relative to the target, even if the target is a mediocre business. The most important question is whether the acquisition generates returns that exceed the acquirer's cost of capital over the long term.
Advantages
- Immediately increases earnings per share, signaling financial discipline
- Demonstrates that the target's earnings justify the acquisition price
- Often received positively by investors and analysts
- Can boost the acquirer's stock price if the market views the deal favorably
Limitations
- Does not account for long-term strategic value or risk of integration failure
- Can be manipulated through aggressive cost-cutting assumptions
- Stock-financed deals by high-P/E acquirers can appear accretive even when overpaying
- Ignores the opportunity cost of alternative uses for the acquisition capital
Frequently Asked Questions
Related Terms
Browse more definitions in the financial terms glossary.